AstraZeneca breast cancer drug fails to win FDA panel backing
Updated
Updated · Bloomberg · Apr 30
AstraZeneca breast cancer drug fails to win FDA panel backing
9 articles · Updated · Bloomberg · Apr 30
The FDA's Oncology Drugs Advisory Committee voted 6-0 that the medicine showed no meaningful benefit for a subtype of metastatic breast cancer.
Panel members objected to the trial design, which assessed patients while on hormone therapy and before an imaging scan, raising concerns about how the results would translate clinically.
The decision creates a setback for a key AstraZeneca pipeline candidate, though the FDA is not bound by advisory committee recommendations.
Could the FDA's caution on AstraZeneca's camizestrant reshape the future of ctDNA-driven cancer treatments and trial design?
How will AstraZeneca's setback affect the competitive race for next-generation oral SERDs in advanced breast cancer?
With serious side effects and uncertain survival benefit, should patients push for access to experimental therapies like camizestrant?